New Cancer Drug Could Aid Biliary Tract Patients
Adults with biliary tract cancer may gain a new first-line option if China's Priority Review leads to approval.
Updated on Nov. 5, 2026 in Cancer
China's National Medical Products Administration granted Priority Review to ivonescimab combined with chemotherapy for first-line biliary tract cancer, following Akeso's Phase III HARMONi-GI1 trial, which met its primary overall survival endpoint against durvalumab plus chemotherapy. The review designation is expected to speed regulatory evaluation for patients with this cancer.
Why it matters
Biliary tract cancer is a difficult-to-treat malignancy, and a first-line regimen that improves overall survival would be a meaningful change in how patients are treated. The Priority Review reflects regulators' view that the unmet need is significant, though approval is not yet granted.
The HARMONi-GI1 study is a randomized, double-blind, multicenter Phase III trial comparing ivonescimab plus chemotherapy with durvalumab plus chemotherapy. It met its primary overall survival endpoint in a prespecified interim analysis reviewed by an Independent Data Monitoring Committee, and it met all key secondary endpoints.
The players
Akeso
A Chinese biopharmaceutical company with a pipeline of more than 50 innovative assets, including eight commercially available drugs and ivonescimab in multiple Phase III cancer studies.
Summit Therapeutics
A biopharmaceutical company that licensed ex-China rights to ivonescimab from Akeso and is developing it for cancer treatment in the United States, Canada, Japan and Europe.
National Medical Products Administration
China's national regulator for drugs and medical products, responsible for reviewing and approving new therapies.
ECOG-ACRIN Cancer Research Group
A U.S. cooperative clinical trials group that conducts multicenter cancer research and studies.
The details
Ivonescimab is a bispecific antibody designed to block two immune-related targets at once, which is the basis for comparing it against the established PD-L1 inhibitor durvalumab. In HARMONi-GI1, patients were randomized to receive either ivonescimab with chemotherapy or durvalumab with chemotherapy, and an independent committee reviewed the interim data. Results were presented as a Late-Breaking Abstract at the ESMO Presidential Symposium in October 2026.
Timeline
October 2026: HARMONi-GI1 results presented at the ESMO Presidential Symposium.
October 21, 2026: Summit announced a clinical trial collaboration with ECOG-ACRIN Cancer Research Group.
November 5, 2026: Akeso announced the NMPA Priority Review grant.
Health Landscape
Ivonescimab is being tested in more than 17 Phase III studies worldwide, including seven head-to-head comparisons against PD-1 and PD-L1 therapies that are standard in oncology. The HARMONi-GI1 result adds a first-line overall survival signal in biliary tract cancer to that growing body of evidence.
If you or a family member have been diagnosed with biliary tract cancer, this development is worth discussing with your oncologist, who can explain what the Priority Review and the trial data may mean for treatment options. Because the regulatory review is still ongoing, the drug is not yet available for routine use.
The takeaway
A Phase III trial meeting its overall survival endpoint is a significant step, but results are interim and regulatory approval remains pending. Anyone with questions about biliary tract cancer treatment should raise them with their oncology care team.
Further reading
For more on how new immunotherapies are being tested against established treatments, see our Cancer coverage.
